Pfizer Raises Annual Guidance as Oncology and Obesity Pipeline Offset COVID Slump

Yahoo Finance reports that Pfizer has increased its full-year revenue outlook by $500 million despite a sharp decline in COVID-related product demand. The pharmaceutical giant is pivoting its strategy toward a non-COVID portfolio that grew 5% this quarter, leaning heavily on the

Yahoo Finance reports that Pfizer has increased its full-year revenue outlook by $500 million despite a sharp decline in COVID-related product demand. The pharmaceutical giant is pivoting its strategy toward a non-COVID portfolio that grew 5% this quarter, leaning heavily on the